The litigation centers on allegations that the company issued misleading statements regarding the NHS-Galleri trial. According to the complaint, defendants concealed material facts about the study's primary endpoint, specifically that the three-year follow-up period was insufficient to demonstrate a reduction in Stage III-IV cancers. The lawsuit claims that while leadership maintained an optimistic outlook, they withheld data suggesting that the statistical goals for the trial were unlikely to be met.

Investors may participate in the action through a contingency fee arrangement, meaning no out-of-pocket costs are required. Those wishing to join or obtain more information can reach out to Phillip Kim at the Rosen Law Firm. As of now, no class has been certified, and investors are not represented by counsel unless they formally retain a firm. Serving as a lead plaintiff is optional, and individual investors may choose to remain absent class members while still retaining the potential to share in any future recovery.